首页> 美国卫生研究院文献>other >A Dual Tracer 18F-FCH/18F-FDG PET Imaging of an Orthotopic Brain Tumor Xenograft Model
【2h】

A Dual Tracer 18F-FCH/18F-FDG PET Imaging of an Orthotopic Brain Tumor Xenograft Model

机译:双示踪剂18F-FCH / 18F-FDG PET成像的原位脑肿瘤异种移植模型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Early diagnosis of low grade glioma has been a challenge to clinicians. Positron Emission Tomography (PET) using 18F-FDG as a radio-tracer has limited utility in this area because of the high background in normal brain tissue. Other radiotracers such as 18F-Fluorocholine (18F-FCH) could provide better contrast between tumor and normal brain tissue but with high incidence of false positives. In this study, the potential application of a dual tracer 18F-FCH/18F-FDG-PET is investigated in order to improve the sensitivity of PET imaging for low grade glioma diagnosis based on a mouse orthotopic xenograft model. BALB/c nude mice with and without orthotopic glioma xenografts from U87 MG-luc2 glioma cell line are used for the study. The animals are subjected to 18F-FCH and 18F-FDG PET imaging, and images acquired from two separate scans are superimposed for analysis. The 18F-FCH counts are subtracted from the merged images to identify the tumor. Micro-CT, bioluminescence imaging (BLI), histology and measurement of the tumor diameter are also conducted for comparison. Results show that there is a significant contrast in 18F-FCH uptake between tumor and normal brain tissue (2.65 ± 0.98), but with a high false positive rate of 28.6%. The difficulty of identifying the tumor by 18F-FDG only is also proved in this study. All the tumors can be detected based on the dual tracer technique of 18F-FCH/ 18F-FDG-PET imaging in this study, while the false-positive caused by 18F-FCH can be eliminated. Dual tracer 18F-FCH/18F-FDG PET imaging has the potential to improve the visualization of low grade glioma. 18F-FCH delineates tumor areas and the tumor can be identified by subtracting the 18F-FCH counts. The sensitivity was over 95%. Further studies are required to evaluate the possibility of applying this technique in clinical trials.
机译:低级神经胶质瘤的早期诊断一直是临床医生面临的挑战。使用 18 F-FDG作为放射示踪剂的正电子发射断层扫描(PET)在该领域的应用受到限制,因为正常脑组织中的背景很高。其他放射性示踪剂,例如 18 F-氟胆碱( 18 F-FCH),可以在肿瘤和正常脑组织之间提供更好的对比,但假阳性率较高。在这项研究中,研究了双示踪物 18 F-FCH / 18 F-FDG-PET的潜在应用,以提高PET成像对低品位的敏感性基于小鼠原位异种移植模型的神经胶质瘤诊断。使用具有和不具有来自U87 MG-luc2神经胶质瘤细胞系的原位神经胶质瘤异种移植物的BALB / c裸鼠进行研究。对动物进行 18 F-FCH和 18 F-FDG PET成像,并叠加两次独立扫描获得的图像进行分析。从合并图像中减去 18 F-FCH计数以识别肿瘤。还进行了微CT,生物发光成像(BLI),组织学和肿瘤直径的测量以进行比较。结果显示,肿瘤与正常脑组织之间的 18 F-FCH摄取存在显着差异(2.65±0.98),但假阳性率高达28.6%。这项研究还证明了仅通过 18 F-FDG识别肿瘤的困难。本研究使用 18 F-FCH / 18 F-FDG-PET双重示踪技术可以检测到所有肿瘤,而假阳性是由 18 F-FCH可以消除。双示踪剂 18 F-FCH / 18 F-FDG PET成像具有改善低度神经胶质瘤可视化的潜力。 18 F-FCH划定肿瘤区域,可通过减去 18 F-FCH计数来鉴定肿瘤。灵敏度超过95%。需要进一步的研究来评估将该技术应用于临床试验的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号